Kiniksa Pharmaceuticals International (KNSA) Operating Leases (2019 - 2026)

Kiniksa Pharmaceuticals International has reported Operating Leases for 8 years, with the latest figure at $5.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 23.19% year-over-year to $5.9 million; the trailing twelve-month figure through Mar 2026 stood at $5.9 million (down 23.19% YoY), and the FY2025 full-year result was $6.5 million, down 17.2% from the prior year.
• Operating Leases for Q1 2026 stood at $5.9 million, down from $6.5 million in the prior quarter.
• The five-year high for Operating Leases was $11.3 million in Q2 2023, with the low at $1.3 million in Q2 2022.
• Historically, Operating Leases has averaged $6.7 million across 5 years, with a median of $7.2 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Leases tumbled 63.49% — and 2023, when it soared 782.86%.
• Kiniksa Pharmaceuticals International's Operating Leases stood at $2.6 million in 2022, then jumped by 282.16% to $10.0 million in 2023, then fell by 21.42% to $7.9 million in 2024, then retreated by 17.2% to $6.5 million in 2025, then declined by 10.06% to $5.9 million in 2026.
• The last three Operating Leases figures came in at $5.9 million (Q1 2026), $6.5 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.